Neuroprotection of histone deacetylase inhibitor TMP 269 in cerebral ischemia / reperfusion rat

Shenyi Kuang,Zheng Wang,Lu Su,Xiang Han,Qiang Dong
2018-01-01
Abstract:Ischemia stroke is an important clinical problem with few efficient treatments. Histone deacetylase has been considered to be associated with ischemic stroke. Studies have identified a variant in HDAC9 associated with large-vessel ischemic stroke. Therefore, HDAC9 inhibitors may function as therapeutic drugs to prevent neurological ischemia. It was also reported that HDAC9 contributed to brain microvessel endothelial cell injury, through increasing inflammatory responses and reducing the expression of tight-junction proteins including occludin. TMP269 is a selective HDAC inhibitor, but it remains poorly characterized in field of stroke. Therefore, we tested TMP269 in a rat model of transient middle cerebral artery occlusion (tMCAO). Sprague-Dawley rats (male, 250-280 g) were randomly assigned to three groups: ischemia/reperfusion (I/R, n=22), ischemia/reperfusion with TMP269 treatment (TMP269, n=23), and sham surgery (sham, n=18). TMP269 was injected one hour before induction of ischemia. Rats were evaluated for neurological functional outcomes 24 hours after MCAO (n=6/group), and then were sacrificed for HDAC9, and occludin protein quantification by Western blot. Other rats were sacrificed to assess infarct volume and edema rate by 2,3,5-triphenyltetrazolium chloride (TTC) staining (n=6/group), and to investigate histological changes by hematoxylin and eosin (H&E) staining (n=6/group). The results showed that TMP269 improved neurological status and infarct volume, increased occludin protein levels after MCAO, suggesting that TMP269 may provide neuroprotection.
What problem does this paper attempt to address?